




# Hjertesygdom hos Kat - Update 2024



Jørgen Koch, DVM, PhD  
Professor, Head of Cardiology & Section  
Department of Veterinary Clinical Sciences  
16 Dyrmlægevej, 1870 Frb. C  
Faculty of Health and Medical Sciences  
University of Copenhagen  
Email: [koch@sund.ku.dk](mailto:koch@sund.ku.dk)












# Hjerteklinikken





# The Heart as a Symbol



*Milton Glaser, I Love New York, 1977.  
Trademarked logo, New York State  
Department of Economic  
Development, New York, New York*


## Red Heart Emoji



*ca. 510-490 BC. Cyrenian  
coin with a silphium seed  
imprinted in it*




*"The Heart Offering," 1338-1344*



<https://ideas.ted.com/how-did-the-human-heart-become-associated-with-love-and-how-did-it-turn-into-the-shape-we-know-today/>





### PUBLIKATIONER KARDIOLOGI

spontaneous pneumothorax secondary to granulomatous pneumonia caused by *Angiostrengylar viscosum* in a dog in Denmark

### ARTICLE IN PRESS

### pathogens

#### Hemostatic Dysfunction in Dogs Naturally Infected with Angiostrengylar cause - A Narrative Review

John L. Williams, M. Victoria Lopez and Lisa M. Ross

**Abstract.** This narrative review provides an overview of the current knowledge regarding hemostatic dysfunction in dogs naturally infected with Angiostrengylar cause. The review covers the epidemiology, clinical signs, laboratory findings, and management of this condition. The authors discuss the role of Angiostrengylar cause in the pathogenesis of hemostatic dysfunction and the importance of early diagnosis and treatment. The review also highlights the need for further research to better understand the underlying mechanisms of this condition and to develop more effective treatments.

### Veterinary Pathology

### CASE REPORT

#### Thromboelastography-guided transfusion in dogs with hypocoagulable disorders: a case series

John L. Williams, M. Victoria Lopez, Lisa M. Ross, and Lisa M. Ross

**Background.** Thromboelastography (TEG) is a point-of-care laboratory test that provides real-time information on the viscoelastic properties of whole blood. It is used to assess the function of platelets and the fibrinolytic system. TEG-guided transfusion has been shown to be effective in managing hypocoagulable disorders in dogs. This case series reports the use of TEG-guided transfusion in a series of dogs with hypocoagulable disorders.

### The Danish Feline Heart study

STAGE	MI	II	III	IV	V	VI	VII	VIII	IX	X	XI	XII
MI	1	1	1	1	1	1	1	1	1	1	1	1
II	1	1	1	1	1	1	1	1	1	1	1	1
III	1	1	1	1	1	1	1	1	1	1	1	1
IV	1	1	1	1	1	1	1	1	1	1	1	1
V	1	1	1	1	1	1	1	1	1	1	1	1
VI	1	1	1	1	1	1	1	1	1	1	1	1
VII	1	1	1	1	1	1	1	1	1	1	1	1
VIII	1	1	1	1	1	1	1	1	1	1	1	1
IX	1	1	1	1	1	1	1	1	1	1	1	1
X	1	1	1	1	1	1	1	1	1	1	1	1
XI	1	1	1	1	1	1	1	1	1	1	1	1
XII	1	1	1	1	1	1	1	1	1	1	1	1

### Small Article

#### Clinical bleeding diathesis, laboratory hemostatic aberrations and survival in dogs infected with Angiostrengylar cause: 180 cases (2005-2019)

John L. Williams, M. Victoria Lopez, Lisa M. Ross, and Lisa M. Ross

**Background.** Angiostrengylar cause is a zoonotic bacterium that can cause hemostatic dysfunction in dogs. This study reports the clinical signs, laboratory findings, and survival of 180 dogs infected with Angiostrengylar cause between 2005 and 2019.

### Small Article

#### Effect of the novel hemostatic agent tranexamsylate (TAM) on platelet aggregation in dogs with hypocoagulable disorders

John L. Williams, M. Victoria Lopez, Lisa M. Ross, and Lisa M. Ross

**Background.** Tranexamsylate (TAM) is a hemostatic agent that has been shown to be effective in managing hypocoagulable disorders in dogs. This study reports the effect of TAM on platelet aggregation in dogs with hypocoagulable disorders.

### Small Article

#### Change of fibrinogen and platelet aggregation in dogs with hypocoagulable disorders

John L. Williams, M. Victoria Lopez, Lisa M. Ross, and Lisa M. Ross

**Background.** Fibrinogen and platelet aggregation are important components of the hemostatic system. This study reports the change of fibrinogen and platelet aggregation in dogs with hypocoagulable disorders.

### Small Article

#### Effect of tranexamsylate (TAM) on platelet aggregation in dogs with hypocoagulable disorders


John L. Williams, M. Victoria Lopez, Lisa M. Ross, and Lisa M. Ross

**Background.** Tranexamsylate (TAM) is a hemostatic agent that has been shown to be effective in managing hypocoagulable disorders in dogs. This study reports the effect of TAM on platelet aggregation in dogs with hypocoagulable disorders.



# Phylogenetic Tree of Cat Breeds

- Genomics 2008 Jan;91(1):12-21.
- doi: 10.1016/j.ygeno.2007.10.009. Epub 2007 Dec 3.






# A Heart-Sick Cat





# Cardiomyopathies - Classifications








Primary and Secondary Cardiomyopathies

<https://www.hospitalsenhedmidt.dk/patientvejledninger/hjertesygdomme/familiaer-dilateret-kardiomyopati-dcm/>



### ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats

Virginia Luis Fuentes, Jonathan Abbott, Valérie Chetboul, Etienne Côté, Philip R. Fox, Jens Häggström, Mark D. Kittleson, Karsten Schober, Joshua A. Stern




#### Transient Myocardial Thickening in Cats Associated with Heart Failure

J. Nord, M. Nord, S. Perera, T. Glavin, L. Wilton, S. Bergqvist, J. Lounsbury. See all authors v



First published 15 December 2017 | <https://doi.org/10.1111/jvim.14887> | CiteSpace: 10

This study was not supported by any grant. This work was done at the Royal Veterinary College, Veterinary Faculty, Highcroft Veterinary Referrals and North Queens Specialist Referrals. The results of this study were presented at an abstract at the 2016 ACVIM-CA Annual Congress 2016, Gothenburg, Sweden.



Journal of Veterinary Cardiology  
Volume 23, Issue 1, February 2013, Pages 14-21  
Echocardiographic assessment of feline false tendons and their relationship with focal thickening of the left ventricle  
D.A. Ruff-Dunn, M. Ingwood, D.L. Hill, S.C. West, D.M. Pinedo, D. Hahn, T.A. Br...

- HCM is a primary disease of the cardiac muscle that is characterized by a hypertrophied and nondilated left ventricle, normal or enhanced contractile function, and impaired ventricular relaxation in the absence of other cardiac or systemic diseases





# Hjertesygdom vs. hjertesvigt



1 ud af 7 katte har  
en hjertelidelse





Medfødte  
<5%?

Erhvervede  
95%?



# Complications

- Congestive Heart Failure
- Dynamic Obstruction of the Left Ventricular Outflow Tract (SAM)
- Thromboembolism
- Arrhythmias
  - Atrial Fibrillation
  - Ventricular Tachycardia
- Sudden Death
- (Anorexia/Weight Loss)





# Clinical Findings


- Any age
- Murmur
  - Harsh systolic ejection murmur across entire precordium → apex & heart base
  - MR: separate murmur - severity of MR related to degree of outflow obstruction
- Gallop sounds
- Dyspnea
- Depression and anorexia
  - Weight loss!?
- Hind limb paralysis
- Syncope
- Sudden death



# Maine Coon with Severe HCM

"Al Pacino" intact  
male, 4 years old

- Atrial Fibrillation
- Congestive  
Heart Failure
- Thromboembolic  
Disease





# TREATMENT OF CONGESTIVE HEART FAILURE IN CATS

- Treatment
  - Oxygen
  - Butorphanol
  - Furosemide
  - Thoracocentesis



## CASE – L...




### Signalement:

- Norwegian Forrest cat
- 4,8 years old
- Neutered female
- 7,3 kg

- Presentation

Gained weight → 0,5-1 kg the last month





# Initial Problem List

## 1. Weight Gain

1. A recent increase in weight despite diet-prescription food

## 2. Increased Abdominal Size


1. Possible causes: fluid accumulation, organ enlargement, or fat deposition

## 3. Hypertrophic Cardiomyopathy (HCM)



1. A chronic condition requiring ongoing treatment with Clopidogrel and Atenolol
2. Arrhythmia



ECHO  
SAX –  
heart base  
(RS)







# Alternative treatment for cats with HCM

- Nattokinase: 3-4 capsules bid (starting with 15 Capsules) 2,000 FU (fibrinolytic units)

Nattokinase is an enzyme derived from natto, a traditional Japanese fermented soybean dish



How it works	
Fibrinolytic Activity	Dissolves fibrin and hereby clots
Blood thinning	By promoting fibrinolysis, it can also help maintain healthy blood flow and circulation
Antihypertensive effects	Antihypertensive effects by promoting vasodilation and enhancing blood flow
Anti-inflammatory properties	Inhibits the expression of certain pro-inflammatory mediators and hereby damps the inflammatory response





# Alternative treatment for cats with HCM

- Rutin: 1 tablet BID (450 mg)  
Rutin is a bioflavonoid, a type of plant pigment found in certain fruits, vegetables, and herbs.



How it works	
Antioxidant activity	Can neutralize harmful free radicals in the body
Anti-inflammatory effects	Inhibiting the production and activity of pro-inflammatory molecules
Vascular health	Strengthening blood vessels and reducing permeability. This prevents leakage of fluid and nutrients into surrounding tissues
Cardiovascular protection	Lowering blood pressure, inhibiting platelet aggregation, diuresis
Anti-allergenic properties	Inhibit the release of histamine and other inflammatory mediators involved in allergic reactions
Skin health	Protects against oxidative damage caused by UV radiation and environmental pollutants

# Asymptomatic Hypertrophic Cardiomyopathy: Diagnosis and Therapy




Virginia Luis Fuentes, VetMB, PhD, CertVR, DVC, MRCVS<sup>a,\*</sup>,  
Lois J. Wilkie, BSc, PhD, MRCVS<sup>b</sup>

Vet Clin Small Anim 47 (2017) 1041–1054  
<http://dx.doi.org/10.1016/j.cvsm.2017.05.002>  
0195-5616/17/© 2017 Elsevier Inc. All rights reserved.

**Table 1**

Prevalence of heart murmurs and hypertrophic cardiomyopathy in 780 apparently healthy cats from rehoming centers






From Payne JR, Brodbelt DC, Luis Fuentes V. Cardiomyopathy prevalence in 780 apparently healthy cats in rehoming centres (the CatScan study). J Vet Cardiol 2015;17:5252; with permission.



# Substantial morbidity and mortality



- HCM is common with an overall prevalence of 15% (CatScan study)
- 28% cardiac mortality at 10 years. (Reveal study)
  - No difference between HCM and OHCM in time to CHF or ATE






# Staging Feline Cardiomyopathy

Journal of Veterinary Internal Medicine

CONSENSUS STATEMENT |

**ACVIM consensus statement guidelines for the classification, diagnosis, and management of cardiomyopathies in cats**

Virginia Luis Fuentes , Jonathan Abbott, Valérie Chetboul, Etienne Côté, Philip R. Fox, Jens Häggström, Mark D. Kittleson, Karsten Schober, Joshua A. Stern



- Gallop sounds
- Arrhythmia
- Poor LA function
- Extreme LV hypertrophy
- LV systolic dysfunction
- "Smoke" / intracardiac thrombus
- Regional LV wall thinning/hypokinesis









# Exploration in the microworld of the myocyte



photo: Carli Hækkerup




# Muscle Contraction



Cardiac myosin-binding protein C, arrayed transversely along the sarcomere, binds myosin and, when phosphorylated, modulates contraction:

- Not essential for cardiac development and function, but involved in determining efficiency of muscle contraction




[www.banyantree.org/jsale/develop.html](http://www.banyantree.org/jsale/develop.html)

Morita et al. (2005) *J. Clin. Invest.* **115**:518–526


# Sarcomeropathy

SEM. Venstre ventrikel, DSH, 6 år








# Sarcomer – multiprotein complexes



# Muscle Contraction



[www.banyantree.org/jsale/develop.html](http://www.banyantree.org/jsale/develop.html)

Cardiac myosin-binding protein C, arrayed transversely along the sarcomere, binds myosin and, when phosphorylated, modulates contraction:


- Not essential for cardiac development and function, but involved in determining efficiency of muscle contraction

*Morita et al. (2005) J. Clin. Invest. 115:518–526*

# Cat (*Felix catus/i*)

- Lifespan - up to 24 years
- 38 chromosomes
- > 350 genetical diseases
- Burmese "Cinnamon", 4 years old
  - 2007
  - 20285 genes
  - $2.7 \times 10^9$  base pair
    - A,T,C,G

Our feline friends share 90% of homologous genes with us







# Genetic Disorders = diseases caused by mutations in one or more genes

- Genes: exons, introns, alleles
  - Transcription
  - Translation


## Modes of Inheritance

- Autosomal Dominant Inheritance
- Autosomal Recessive Inheritance
- X-Linked Dominant Inheritance
- Y-Linked Inheritance
- Mitochondrial Inheritance
- Multifactorial Inheritance




<https://drbillspetnutrition.com/feline-genetic-diseases/>

# Types of Mutations



Phenotype =  
Genotype x Environment

- Insertions and Deletions (Indels)
- Frameshift Mutations
- Splice Site Mutations
- Repeat Expansion



**Figure 3. Determinants of phenotype in HCM**  
Selected factors contributing to expression of cardiac phenotype in HCM are shown. The causal mutation imparts the main effect and several others, such as other pathogenic genetic variants (modifiers), genomics (such as non-coding RNAs), proteomics (such as post-translational modifications), and environmental factors (such as isometric exercises) contributing to expression of the phenotype.

# Sarcomeropathies (humans)

A. Established Causal Gene HCM (Large families)				
Gene	Protein	Function	Tolerance to variation	
			Missense (Z score)	LoF (pLI)
<i>MYH7</i>	β-Myosin heavy chain	ATPase activity, Force generation	6.54	0.00
<i>MYBPC3</i>	Myosin binding protein-C	Cardiac contraction	0.69	0.00
<i>TNNT2</i>	Cardiac troponin T	Regulator of acto-myosin interaction	1.54	0.01
<i>TNNI3</i>	Cardiac troponin I	Inhibitor of acto-myosin interaction	1.88	0.17
<i>TPM1</i>	α-tropomyosin	Places the troponin complex on cardiac actin	3.42	0.80
<i>ACTC1</i>	Cardiac α-actin	Acto-myosin interaction	5.25	0.95
<i>MYL2</i>	Regulatory myosin light chain	Myosin heavy chain 7 binding protein	0.86	0.02
<i>MYL3</i>	Essential myosin light chain	Myosin heavy chain 7 binding protein	0.75	0.89
<i>CSRP3</i>	Cysteine and glycine-rich protein 3	Muscle LIM protein (MLP), a Z disk protein	-0.66	0.00

B. Likely causal genes for HCM (small families)				
Gene	Protein	Function	Tolerance to variation	
			Missense (Z score)	LoF (pLI)
<i>FHL1</i>	Four-and-a-half LIM domains 1	Muscle development and hypertrophy	1.29	0.92
<i>MYOZ2</i>	Myozenin 2 (calsarcin 1)	Z disk protein	0.03	0.02
<i>PLN</i>	Phospholamban	Regulator of sarcoplasmic reticulum calcium	0.57	0.11
<i>TCAP</i>	Tcap (Telethonin)	Titin capping protein	0.45	0.08
<i>TRIM63</i>	Muscle ring finger protein 1	E3 ligase of proteasome ubiquitin system	0.02	0.00
<i>TTN</i>	Titin	Sarcomere function	-5.48	0.00




Figure 1. HCM as a disease of sarcomere proteins  
A schematic structure of a sarcomere composed of thick and thin filaments and Z discs is depicted along with its protein constituents involved in HCM. Established causal genes for HCM and their population frequencies are listed.

C. Genes associated with HCM				
Gene	Protein	Function	Tolerance to variation	
			Missense (Z score)	LoF (pLI)
<i>ACTN2</i>	Actinin, alpha 2	Z disk protein	1.76	1.0
<i>ANKRD1</i>	Ankyrin repeat domain 1	A negative regulator of cardiac genes	-0.01	0.00
<i>CASQ2</i>	Calciosquemin 2	Calcium binding protein	-1.08	0.00
<i>CAV3</i>	Carveolin 3	A caveolae protein	1.19	0.34
<i>JPH2</i>	Juncophilin2	Intracellular calcium signaling	3.93	0.01
<i>LDB3</i>	Lim domain binding 3	Z disk protein	0.32	0.00
<i>MYH6</i>	Myosin heavy chain alpha	Sarcomere protein expressed at low levels in the adult human heart	2.87	0.00
<i>MYLK2</i>	Myosin light chain kinase 2	Phosphorylate myosin light chain 2	0.73	0.22
<i>NEFN</i>	Nexlin	Z disc protein	-1.32	0.00
<i>TNNC1</i>	Cardiac troponin C	Calcium sensitive regulator of myofibrilment function	2.22	0.51
<i>VCL</i>	Vinculin	Z disk protein	3.11	0.99

The Z score for each gene reflects deviation of the observed variants in the ExAC database from the expected number. A higher positive Z score indicates that the gene is intolerant to variation. Likewise, pLI indicates probability of intolerance to Loss-of-Function (LoF) variants with 1 indicating total intolerance.



# Feline HCM – American College of Medical Genetics Guidelines

Protein	Mutation	Breed	Classification
MYBPC3	A31P	MCO	Pathogenic
MYBPC3	R820W	Ragdoll	Pathogenic
<i>Alstrom syndrome protein 1</i>	<i>p.G3376R</i>	Sphynx	Unknown significance
TroponinT2	TNNT2 c.95-108G>A	MCO	Unknown significance
MYH7	E1883K	DSH	Likely pathogenic

A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy ©  
 Kathryn M. Meier, M. Vanessa Sanchez, Ryan M. David, Neil E. Bowles, Jeffrey A. Towbin, Peter J. Reber, Judith A. Kittleson, Marco J. Munro, Keith Dryburgh, Kristin A. Macdonald  
 — Show more  
*Journal of Molecular Genetics*, Volume 14, Issue 73, 1 December 2019, Pages 3047–3053


Genomics  
 Volume 19, Issue 1, August 2017, Pages 261–264

A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy  
 Kathryn M. Meier, M. Vanessa Sanchez, Ryan M. David, Neil E. Bowles, Jeffrey A. Towbin, Peter J. Reber, Judith A. Kittleson, Marco J. Munro, Keith Dryburgh, Kristin A. Macdonald  
 — Show more  
*Journal of Molecular Genetics*, Volume 14, Issue 73, 1 December 2019, Pages 3047–3053



*A relatively limited number of mutations identified → The genetic architecture of feline HCM susceptibility may follow an oligogenic or polygenic mode of inheritance.*

# Pathogenesis – Feline HCM




## Feline Hypertrophic Cardiomyopathy Associated with the p-A31P Mutation in cMyBP-C Is Caused by Production of Mutated cMyBP-C with Reduced Binding to Actin

Mia T. N. Godiksen<sup>1,2</sup>, Craig Kincaid<sup>3</sup>, Tina Ravnsborg<sup>4</sup>, Peter Hajrup<sup>4</sup>, Sara Granström<sup>1,2</sup>, Inga A. Laurisen<sup>1</sup>, Paula L. Hedley<sup>1,2</sup>, Johanna C. Moelmas Simons<sup>5</sup>, William J. McKenna<sup>6</sup>, Jørgen Koch<sup>7</sup>, Michael Christensen<sup>1,2</sup>

<sup>1</sup>Department of Clinical Biochemistry and Immunology, Statens Serum Institut, Copenhagen, Denmark  
<sup>2</sup>Department of Small Animal Diseases, Faculty of Life Science, University of Copenhagen, Copenhagen, Denmark  
<sup>3</sup>ARC Centre for Molecular and Cellular Biology, University of Stellenbosch, Cape Town, South Africa  
<sup>4</sup>Institute of Biochemistry and Molecular Biology, University of Southern Denmark, Odense, Denmark  
<sup>5</sup>Institute of Cardiovascular Science, The Heart Hospital, University College London, London, UK  
Email: [mie@ssi.ssi.dk](mailto:mie@ssi.ssi.dk)

Received February 7, 2013; revised March 7, 2013; accepted April 7, 2013

Copyright © 2013 Mia T. N. Godiksen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Figure 6.** Schematic visualization of the effect of substituting the alanine residue with a proline residue. The proline interrupts the hydrogen bond between two beta strands. (a) Close-up of the alanine residue in the beta strand; (b) Close-up of the C0 domain with the alanine substituted by trans-proline; (c) Close-up of the C0 domain with the alanine substituted by cis-proline.

Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy

Lislotte B. Christensen,<sup>1,2</sup> Flemming Deba,<sup>2</sup> Jørgen Koch,<sup>1</sup> Christina N. Hansen,<sup>2</sup> Pall S. Leifsson,<sup>3</sup> and Takashi Yokota<sup>4</sup>

<sup>1</sup>Department of Veterinary Clinical and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; <sup>2</sup>Department of Biomedical Sciences, Center for Healthy Aging, University of Copenhagen, Copenhagen, Denmark; and <sup>3</sup>Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark


Submitted 10 October 2014; accepted in final form 10 March 2015

# Pathogenesis of fHCM



Tertiary (histological) phenotypes



- Myocyte hypertrophy
- Myocyte disarray
- Interstitial fibrosis
- Cardiac hypertrophy



Septum, 20x, Masson's trichrome




40x. Vessel




# Cardiac Myocytes

Normal alignment



BSH, male, 2 years-old



HCM

*Photo: Assoc.prof. Pall S. Leifsson, IVH, KU*


Myocyte disarray

# Pathogenesis

Quaternary (clinical) phenotypes



▼  
Cardiac arrhythmias  
Sudden cardiac death  
left ventricular outflow tract obstruction  
Heart failure



https a31p mutation

KUnet forsider itslearning

In the Maine Coon breed, the **A31P mutation** in the cardiac myosin binding protein C gene (MYBPC3) has been found to be associated with increased risk for ...

[\[PDF\] Myosin-Binding Protein C DNA Variants in Domestic Cats \(A31P ...](#)  
[www.vetogene.com/GATTI/upload/jvim12031.pdf](http://www.vetogene.com/GATTI/upload/jvim12031.pdf) ▾ [Oversæt denne side](#)  
efter M Longeri - 2013 - [Relaterede artikler](#)  
HCM was most prevalent in MCO homozygote for the **A31P mutation** and the ...  
Conclusions and Clinical Importance: **A31P mutation** occurs frequently in MCO ...

[Prevalence of the MYBPC3-A31P mutation in a large European ...](#)  
[www.ncbi.nlm.nih.gov/pubmed/21051304](http://www.ncbi.nlm.nih.gov/pubmed/21051304) ▾ [Oversæt denne side](#)  
efter J Mary - 2010 - [Citeret af 7](#) - [Relaterede artikler](#)  
03/11/2010 - OBJECTIVES: The MYBPC3-**A31P mutation** has been identified in the USA in a colony of Maine Coon cats with an autosomal dominant ...


[\[PDF\] View and print](#)  
[www.langfordvets.co.uk/.../HCM\\_statement\\_UCD\\_L...](http://www.langfordvets.co.uk/.../HCM_statement_UCD_L...) ▾ [Oversæt denne side](#)  
Two recent papers have shown that not all Maine Coon cats with the **A31P mutation** get HCM (3, 4) and one of those papers has mistakenly interpreted this lack ...

[Genomia: HCM in Maine Coon](#)  
[www.genomia.cz/en/test/hcm-main-coon/](http://www.genomia.cz/en/test/hcm-main-coon/) ▾ [Oversæt denne side](#)  
HCM in Maine Coon cats - detetion of Meurs **mutation (A31P)**; Koch **mutation ( A74T)** is not included but it is possible to order it (detection for free)

[Prevalence of the MYBPC3-A31P mutation in a ... - ResearchGate](#)  
[www.researchgate.net/.../47678884\\_Prevalence\\_of\\_t...](http://www.researchgate.net/.../47678884_Prevalence_of_t...) ▾ [Oversæt denne side](#)  
Publication » Prevalence of the MYBPC3-**A31P mutation** in a large European feline population and association with hypertrophic cardiomyopathy in the Maine ...

[Prevalence of the MYBPC3-A31P mutation in a ... - ScienceDirect](#)  
[www.sciencedirect.com/science/.../S17602734100005...](http://www.sciencedirect.com/science/.../S17602734100005...) ▾ [Oversæt denne side](#)  
efter J Mary - 2010 - [Citeret af 7](#) - [Relaterede artikler](#)  
03/11/2010 - The MYBPC3-**A31P mutation** has been identified in the USA in a colony of Maine Coon cats with an autosomal dominant hypertrophic ...

[Hypertrophic cardiomyopathy in young Maine Coon cats caused by ...](#)  
[link.springer.com/article/10.1186%2F1751-0147-53-7](http://link.springer.com/article/10.1186%2F1751-0147-53-7) ▾ [Oversæt denne side](#)  
efter MTN Godiksen - 2011 - [Citeret af 3](#) - [Relaterede artikler](#)  
Hypertrophic cardiomyopathy in young Maine Coon cats caused by the p.**A31P** cMyBP-...





# HCM in Cats



- Pathology:
  - Measure heart weight!
    - Normal < 20 g in a 5 kg cat
    - 0.35% of bodyweight
  - Heart weight from severe HCM affected cats often > 30-45 gram



Affected  
BSH, male, 4 years-old



### HCM screening within health programme

Participating clubs: Maine Coon-katten, Sällskapet Sibirisk Katt, Skogkattsligan, Rex United, Skogkattklubben Birka, Rasclub Maine Coon, Scandinavian Ragdoll Club, Birmasällskapet, SWEPEX (Svenska Perser & Exotikringen), Ragdollklubben  
 Visit <http://www.pawpeds.com/healthprogrammes/> for more information

Patient Information		Owner's name
Cat's registered name	Address	
Registration number	Postcode/City/State	
ID number, microchip or tattoo	Country	
Race	Phone (including country code)	
Male <input type="checkbox"/> Not altered Female <input type="checkbox"/> Altered	Email	
Born (year-month-day)	I am aware that the results will be retained for the records of Maine Coon-katten. I authorize Maine Coon-katten to publicly release all results from this form.	
Site	Signature	Date
Exam		
Examination		
Sedated	Examination date (year-month-day)	
Yes, with:	No	
Weight _____ kg	Auscultation:	
Heart rate _____ bpm	Normal _____ Gallop _____	
Dehydrated _____	Murmur, characteristics	
Lactating _____	Grade: I II III IV V VI Dynamic _____ Static _____	
	Timing: Systolic Diastolic Both Continuous	
	Location: Left apex (sternum) Left Base Other, describe _____	
IVSd _____ cm mm	M-mode 2-D	Subjective left atrial size
LVIDd _____	M-mode 2-D	Normal
LVPWd _____	M-mode 2-D	Mild enlargement
IVSs _____	M-mode 2-D	Moderate enlargement
LVIDs _____	M-mode 2-D	Severe enlargement
LVPWs _____	M-mode 2-D	Systolic anterior motion of the mitral valve yes no
SF _____	M-mode 2-D	If yes, LV outflow tract flow velocity (Doppler) _____
Ao _____	M-mode 2-D	End-systolic cavity obliteration yes no
LA _____	M-mode 2-D	Papillary muscles
LA/Ao _____	M-mode 2-D	Normal
		Abnormal, moderate enlargement
		Abnormal, severe enlargement
Assessment (based on phenotype)		
Normal		
Equivocal		
HCM Mild Moderate Severe		
Other, describe _____		
Veterinarian		
Veterinarian's name, clinic's name and address		
Cat's identity verified yes no, describe why not		
Signature	Date	

For registration of the result, the veterinarian shall send a copy of this form to:  
 Maine Coon-katten, c/o Anne N. Jensen, Landsvinget 5, Nejsede, 3400 Hillerød, Denmark

Rev 1.5 (en) 2007-03-04



## Effect of Body Weight on Echocardiographic Measurements in 19,866 Pure-Bred Cats with or without Heart Disease

J. Häggström, Å.O. Andersson, T. Falk, L. Nilfors, U. Olsson, J.G. Kresken, K. Höglund, M. Rishniw, A. Tidholm, and I. Ljungvall

**Background:** Echocardiography is a cost-efficient method to screen cats for presence of heart disease. Current reference intervals for feline cardiac dimensions do not account for body weight (BW).**Objective:** To study the effect of BW on heart rate (HR), aortic (Ao), left atrial (LA) and ventricular (LV) linear dimensions in cats, and to calculate 95% prediction intervals for these variables in normal adult pure-bred cats.**Animals:** 19 866 pure-bred cats.**Methods:** Clinical data from heart screens conducted between 1999 and 2014 were included. Associations between BW, HR, and cardiac dimensions were assessed using univariate linear models and allometric scaling, including all cats, and only those considered normal, respectively. Prediction intervals were created using 95% confidence intervals obtained from regression curves.**Results:** Associations between BW and echocardiographic dimensions were best described by allometric scaling, and all dimensions increased with increasing BW (all  $P < 0.001$ ). Strongest associations were found between BW and Ao, LV end diastolic, LA dimensions, and thickness of LV free wall. Weak linear associations were found between BW and HR and left atrial to aortic ratio (LA:Ao), for which HR decreased with increasing BW ( $P < 0.001$ ), and LA:Ao increased with increasing BW ( $P < 0.001$ ). Marginal differences were found for prediction formulas and prediction intervals when the dataset included all cats versus only those considered normal.**Conclusions and Importance:** BW had a clinically relevant effect on echocardiographic dimensions in cats, and BW based 95% prediction intervals may help in screening cats for heart disease.**Key words:** Heart dimensions; M-mode; Prediction intervals; Screening.

breed, the database consisted of 5,274 Maine Coon, 3,301 Norwegian Forest, 2,663 British Shorthair, 1,832 Siberian, 1,809 Ragdoll, 1,258 Sphynx, 914 Birman, 745 Cornish Rex, 584 Bengal, 526 Devon Rex, 204 Persian, and 756 cats of other breeds. The latter group consisted of 38 different breeds of which British Longhair, European, and Ocicat were the most common (>50 cats per breed).

**Table 1.** Medians and interquartile ranges (IQR) for age, body weight, heart rate, and echocardiographic measurements in all cats, in cats classified as normal, according to stipulated criteria (see materials and methods), and in cats with abnormal findings.

Variable	All (n = 19,866)	Normal (n = 18,460)	Abnormal (n = 1,406)	P-value
Age (years)	1.8 (1.1–3.2)	1.8 (1.1–3.1)	4.5 (1.5–4.5)	<.0001
Body weight (kg)	4.2 (3.5–5.1)	4.2 (3.5–5.1)	4.6 (3.7–5.9)	<.0001
Heart rate (beats/min)	180 (160–196)	180 (160–195)	180 (160–200)	<.0001
IVSd (mm)	3.9 (3.5–4.3)	3.9 (3.5–4.3)	5.2 (4.3–5.9)	<.0001
LVIDd (mm)	15.6 (14.3–17.0)	15.7 (14.3–17.1)	15.0 (13.4–16.7)	<.0001
LVPWd (mm)	3.8 (3.4–4.3)	3.8 (3.4–4.2)	5.1 (4.2–5.8)	<.0001
IVSs (mm)	6.2 (5.5–7.0)	6.2 (5.5–7.0)	7.6 (6.4–8.6)	<.0001
LVIDs (mm)	8.5 (7.3–9.8)	8.5 (7.4–9.8)	7.5 (6.1–9)	<.0001
LVPWs (mm)	6.5 (5.8–7.2)	6.4 (5.7–7.1)	7.7 (6.7–8.8)	<.0001
FS%	45 (39–51)	45 (39–51)	49 (42–56)	<.0001
Ao (mm)	9.3 (8.5–10.2)	9.3 (8.5–10.2)	9.5 (8.8–10.5)	<.0001
LA (mm)	10.8 (9.6–12.0)	10.8 (9.6–12.0)	11.7 (10.0–13.4)	<.0001
LA:Ao	1.14 (1.06–1.24)	1.13 (1.06–1.23)	1.2 (1.10–1.35)	<.0001

IVSd, interventricular septum diastole; LVIDd, left ventricular internal diameter diastole; LVPWd, left ventricular free wall diastole; IVSs, interventricular septum systole; LVIDs, left ventricular internal diameter systole; LVPWs, left ventricular free wall systole; FS%, fractional shortening; Ao, aortic diameter; LA, left atrial diameter; and LA:Ao, left atrial-to-aortic ratio.



# Nye grænseværdier

**Table 3.** Predicted cardiac dimensions and 95% prediction intervals for 18460 cats with normal echocardiograms according to specific, stated criteria (see materials and methods).


Weight (kg)	IVSd (mm)	LVIDd (mm)	LVFWd (mm)	IVSs (mm)	LVIDs (mm)	LVFWs (mm)	FS (%)	LA (mm)	Ao (mm)	LA:Ao
1.5	3.1 (2.3–4.0)	11.9 (9.5–15.0)	2.9 (2.2–3.8)	4.8 (3.5–6.7)	6.4 (4.2–9.6)	4.8 (3.6–6.5)	45 (28–62)	7.7 (5.8–10.2)	7.0 (5.5–8.8)	1.13 (0.85–1.40)
2.0	3.3 (2.5–4.3)	12.8 (10.2–16.0)	3.1 (2.4–4.1)	5.2 (3.7–7.2)	6.9 (4.6–10.5)	5.2 (3.9–7.1)	45 (28–62)	8.5 (6.3–11.2)	7.5 (6.0–9.5)	1.13 (0.85–1.40)
2.5	3.4 (2.6–4.5)	13.6 (10.9–17.0)	3.2 (2.5–4.4)	5.4 (3.9–7.6)	7.4 (4.8–11.2)	5.5 (4.1–7.5)	45 (28–62)	9.1 (6.8–12.0)	8.0 (6.3–10.1)	1.14 (0.86–1.41)
3.0	3.5 (2.7–4.7)	14.2 (11.4–17.8)	3.4 (2.6–4.5)	5.7 (4.1–7.9)	7.7 (5.1–11.7)	5.8 (4.3–7.9)	45 (28–62)	9.6 (7.2–12.7)	8.4 (6.7–10.7)	1.14 (0.86–1.42)
3.5	3.7 (2.8–4.9)	14.8 (11.9–18.5)	3.6 (2.7–4.7)	5.9 (4.2–8.2)	8.0 (5.3–12.2)	6.0 (4.5–8.2)	45 (28–62)	10.0 (7.6–13.4)	8.8 (7.0–11.1)	1.15 (0.87–1.42)
4.0	3.8 (2.8–4.9)	15.4 (12.2–19.2)	3.7 (2.8–4.8)	6.0 (4.3–8.4)	8.3 (5.5–12.6)	6.3 (4.6–8.5)	45 (28–62)	10.5 (7.9–13.9)	9.1 (7.2–11.6)	1.15 (0.88–1.43)
4.5	3.9 (2.9–5.1)	15.8 (12.7–19.8)	3.8 (2.9–5.0)	6.2 (4.4–8.7)	8.6 (5.7–13.0)	6.5 (4.8–8.7)	45 (28–62)	10.9 (8.2–14.5)	9.4 (7.5–11.9)	1.15 (0.88–1.43)
5.0	3.9 (3.0–5.2)	16.3 (13.0–20.3)	3.9 (3.0–5.1)	6.4 (4.6–8.9)	8.8 (5.8–13.4)	6.6 (4.9–9.0)	45 (28–62)	11.2 (8.4–14.9)	9.7 (7.7–12.3)	1.16 (0.88–1.43)
5.5	4.0 (3.0–5.3)	16.7 (13.4–20.9)	4.0 (3.0–5.3)	6.5 (4.7–9.1)	9.0 (6.0–13.7)	6.8 (5.0–9.2)	45 (28–62)	11.6 (8.7–15.4)	10.0 (7.9–12.6)	1.16 (0.89–1.44)
6.0	4.1 (3.1–5.4)	17.1 (13.7–21.4)	4.1 (3.1–5.4)	6.6 (4.7–9.3)	9.3 (6.1–14.1)	7.0 (5.1–9.4)	45 (28–62)	11.9 (8.9–15.8)	10.2 (8.1–12.9)	1.16 (0.89–1.44)
6.5	4.2 (3.1–5.5)	17.4 (14.0–21.8)	4.2 (3.1–5.5)	6.7 (4.8–9.4)	9.4 (6.2–14.3)	7.1 (5.3–9.6)	45 (28–62)	12.2 (9.2–16.2)	10.5 (8.3–13.2)	1.17 (0.90–1.45)
7.0	4.2 (3.2–5.6)	17.8 (14.2–22.2)	4.3 (3.2–5.6)	6.9 (4.9–9.6)	9.6 (6.3–14.6)	7.3 (5.4–9.8)	45 (28–62)	12.5 (9.4–16.6)	10.7 (8.4–13.5)	1.18 (0.90–1.46)
7.5	4.3 (3.2–5.7)	18.1 (14.5–22.6)	4.3 (3.3–5.7)	7.0 (5.0–9.7)	9.8 (6.5–14.9)	7.4 (5.5–10.0)	45 (28–62)	12.7 (9.6–16.9)	10.9 (8.6–13.8)	1.18 (0.91–1.46)
8.0	4.3 (3.3–5.8)	18.4 (14.7–23.0)	4.4 (3.3–5.8)	7.1 (5.1–9.9)	10.0 (6.6–15.1)	7.5 (5.6–10.2)	45 (28–62)	13.0 (9.8–17.3)	11.1 (8.8–14.0)	1.19 (0.91–1.47)
8.5	4.4 (3.3–5.8)	18.7 (15.0–23.4)	4.4 (3.4–5.9)	7.2 (5.1–10.0)	10.1 (6.7–15.4)	7.6 (5.6–10.3)	45 (28–62)	13.2 (10.0–17.6)	11.3 (8.9–14.3)	1.19 (0.92–1.47)
9.0	4.4 (3.3–5.9)	19.0 (15.2–23.7)	4.5 (3.4–5.9)	7.3 (5.2–10.2)	10.3 (6.8–15.6)	7.7 (5.7–10.5)	45 (28–62)	13.5 (10.1–17.9)	11.5 (9.1–14.5)	1.20 (0.92–1.47)
9.5	4.5 (3.4–6.0)	19.3 (15.4–24.0)	4.6 (3.4–5.9)	7.4 (5.3–10.3)	10.4 (6.9–15.8)	7.9 (5.8–10.6)	45 (28–63)	13.7 (10.3–18.2)	11.6 (9.1–14.7)	1.20 (0.92–1.48)
10.0	4.5 (3.4–6.0)	19.5 (15.6–24.4)	4.6 (3.5–6.1)	7.4 (5.3–10.4)	10.5 (6.9–16.0)	8.0 (5.9–10.8)	45 (28–63)	13.9 (10.5–18.5)	11.8 (9.3–14.9)	1.21 (0.92–1.48)
10.5	4.6 (3.5–6.1)	19.8 (15.8–24.7)	4.7 (3.5–6.2)	7.5 (5.4–10.5)	10.7 (7.1–16.3)	8.1 (6.0–10.9)	45 (28–63)	14.1 (10.6–18.8)	11.9 (9.5–15.1)	1.22 (0.94–1.49)
11.0	4.6 (3.5–6.1)	20.0 (16.0–25.0)	4.7 (3.5–6.2)	7.6 (5.4–10.6)	10.8 (7.2–16.5)	8.1 (6.0–11.0)	45 (28–63)	14.3 (10.8–19.1)	12.1 (9.6–15.3)	1.22 (0.94–1.50)

HR, heart rate; IVSd, interventricular septum diastole; LVIDd, left ventricular internal diameter diastole; LVFWd, left ventricular free wall diastole; IVSs, interventricular septum systole; LVIDs, left ventricular internal diameter systole; LVFWs, left ventricular free wall systole; FS%, fractional shortening; Ao, aortic diameter; LA, left atrial diameter; and LA:Ao, left atrial-to-




# Breed-differences in Phenotype

15/12/2014 14:16:52





18/03/2019 11:11:05




193  
1:77HR

11/11/2008 10:25:40




182  
3:120 HR


# HCM in Ragdolls



Healthy Ragdoll



HCM-affected





SPONTANEOUSLY-ARISING DISEASE

## An Immunohistochemical Study of Feline Myocardial Fibrosis

H. Aupperle\*, K. Baldauf† and I. März†

\* *Institute für Veterinär-Pathologie, An den Tierkliniken 33 and † Klinik für Kleintiere, An den Tierkliniken 23, Veterinärmedizinische Fakultät der Universität Leipzig, Germany*




Fig. 3. Microscopic findings in the heart of an 8-year-old DSH cat. (A) Normal myocardium with few collagen fibres (red) between cardiomyocytes. Picrosirius red stain. (B) In the normal myocardium most collagen fibres are of collagen type I (yellow) and few fibres are of collagen type III (green). Picrosirius red stain with polarized light.




Fig. 4. Microscopic findings in the heart of a 7-year-old exotic short hair cat (see also Fig. 2B). (A) Large areas of myocardial fibrosis (red). Picrosirius red stain. (B) The fibrotic areas are mainly composed of type I collagen fibres (yellow). Picrosirius red stain with polarized light.





Fig. 2. (A) Heart from a 14-year-old DSH cat with marked hypertrophy and areas of white scar formation. (B) Heart from a 7-year-old cat with extensive myocardial fibrosis (see Fig. 4), but the papillary endocardiosis (feline endocardiosis).

*Bartonella henselae*







## INFECTIOUS DISEASE

## ***Bartonella* spp. as a Possible Cause or Cofactor of Feline Endomyocarditis—Left Ventricular Endocardial Fibrosis Complex**

T. A. Donovan<sup>\*</sup>, N. Balakrishnan<sup>†</sup>, I. Carvalho Barbosa<sup>‡</sup>, T. McCoy<sup>‡</sup>,  
E. B. Breitschwerdt<sup>‡</sup> and P. R. Fox<sup>§</sup>

<sup>\*</sup>Department of Anatomic Pathology, The Animal Medical Center, New York, New York, <sup>†</sup>Clinical Microbiology Unit, State Laboratory of Public Health, North Carolina Department of Health and Human Services, <sup>‡</sup>Department of Clinical Sciences, and the Intracellular Pathogens Research Laboratory, Comparative Medicine Institute, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina and <sup>§</sup>Department of Cardiology, The Animal Medical Center, New York, New York, USA

### Summary

Endomyocarditis is a commonly detected post-mortem finding in domestic cats presenting for sudden onset cardiovascular death, yet the aetiology remains unresolved. Cats are documented reservoir hosts for *Bartonella henselae*, the infectious cause of cat scratch disease in man. Various *Bartonella* spp. have been associated with culture-negative endocarditis, myocarditis and sudden death in man and animals. We hypothesized that *Bartonella* spp. DNA could be amplified more often from the hearts of cats with feline endomyocarditis—left ventricular endocardial fibrosis (FEMC—LVEF) complex compared with cats with hypertrophic cardiomyopathy (HCM) or cats with grossly and microscopically unremarkable hearts (designated non-cardiac disease controls). Formalin-fixed and paraffin wax-embedded, cardiac tissues from 60 domestic and purebred cats aged 3 months to 18 years were examined, and histological features were recorded. Cardiac tissue sections were tested for *Bartonella* DNA using multiple 16–23S intergenic transcribed spacer region polymerase chain reaction (PCR) primer sets, including two *Bartonella* genera, a *Bartonella koehlerae* species-specific and a *Bartonella vinsonii* subsp. *berkhoffii*-specific assay, followed by DNA sequence confirmation of the species or genotype. Special precautions were taken to avoid DNA cross-contamination between tissues. *Bartonella* spp. DNA was amplified by PCR and sequenced from 18 of 36 cats (50%) with FEMC—LVEF and 1/12 (8.3%) cats with HCM. *Bartonella* spp. DNA was not amplified from any non-cardiac disease control hearts. Based on PCR/DNA sequencing, one *Bartonella* spp. was amplified from 10 cats, while the remaining eight were coinfecting with more than one *Bartonella* spp. To our knowledge, this study represents the first documentation of *B. vinsonii* subsp. *berkhoffii* genotype I infection in cats ( $n = 11$ ). Fluorescence in-situ hybridization testing facilitated visualization of *Bartonella* bacteria within the myocardium of four of seven PCR-positive FEMC—LVEF hearts. Collectively, these findings support the hypothesis that *Bartonella* spp. may play a primary role or act as a cofactor in the pathogenesis of FEMC—LVEF. Studies involving cats from other geographical regions and definitive demonstration of *Bartonella* spp. within regions of inflammation are needed to confirm an association between *Bartonella* spp. and FEMC—LVEF induced morbidity and mortality in cats.



## Bartonella?! (Restrictive Cardiomyopathy)





Fig. 6. Case 33, FEMC–LVEF cohort, subgross image. Left ventricular endocardial and myocardial fibrosis are highlighted by blue staining. Trichrome stain. Bar, 2 mm.



Fig. 4. Case 33, FEMC–LVEF cohort, gross longitudinal four-chamber cardiac dissection. There is severe, generalized left ventricular hypertrophy and mild right ventricular wall thickening. There is marked endocardial thickening associated with fibrosis in the mid to apical left ventricular chamber. Regions of mottling and white discoloration are present within the myocardium (fibrosis). The left atrium is markedly enlarged with diffuse endocardial fibrosis. The left atrioventricular valve is mildly thickened. Bar, 5 mm.

# False Tendons in Humans and Cats



Birman cat, 6Y, Male



## Echocardiographic assessment of feline false tendons and their relationship with focal thickening of the left ventricle

O.A. Wolf, DVM<sup>a</sup>, M. Imgrund, Dr. rer. nat.<sup>b</sup>, G. Wess, DVM, PhD, Dr habil.<sup>a,\*</sup>

<sup>a</sup> Clinic of Small Animal Medicine, Ludwig-Maximilians-University, Veterinaerstr. 13, 80539 Munich, Germany

<sup>b</sup> University Observatory, Ludwig-Maximilians-University, Munich, Germany

Received 31 March 2015; received in revised form 11 March 2016; accepted 29 August 2016

### ANATOMIA HISTOLOGIA EMBRYOLOGIA

JOURNAL OF VETERINARY MEDICINE

Anatomia, Histologia, Embryologia

#### SHORT COMMUNICATION

### Incidence, Distribution and Morphology of Left Ventricular False Tendons in Cat Hearts

Y. Kimura, S. Karakama, M. Kobayashi and N. Machida\*

Address of authors: Laboratory of Veterinary Clinical Oncology, Toyo University of Agriculture and Technology, 3-5-8 Saiwai-cho, Fuchu, Tokyo 183-8509, Japan

\*Correspondence:  
Tel./fax: +81 42 367 5772;  
e-mail: machida@cc.tuat.ac.jp

With 3 figures

Received April 2015; accepted for publication September 2015

doi: 10.1111/ahc.12216

#### Summary

The incidence, distribution, and macro- and microscopic structures of left ventricular false tendons (LVFTs) in the cat heart were studied using 25 normal and 57 diseased hearts. The fibrous bands were observed in the left ventricle of all 82 cat hearts examined and most commonly extended between the papillary muscles and the ventricular septum. Histologically, the LVFTs were composed of central Purkinje fibres and surrounding dense collagenous fibres covered by endothelium. There was no appreciable difference in the incidence, distribution or morphology of LVFTs between the normal and the diseased hearts, indicating that LVFTs are a common anatomic variant in the cat heart.

In conclusion, focal insertion is often associated with increased segmental wall thickness of the IVS in diastole. Although focal hypertrophy can occur with feline HCM, the FT-regions did not apparently change over time when compared with non-FT regions. Furthermore, there was no obvious relationship with other forms of LV hypertrophy during routine echocardiographic examinations. The mean growth at the FT-region did not significantly differ from the growth at the non-FT region at follow-up examinations, suggesting that these regions might be normal variation or of little clinical significance to non-breeding cats. It is important to carefully scrutinize focal thickening in an echocardiographic examination and review echocardiographic loops and 2D images for FT insertions. Furthermore, care must be taken to not make erroneous measurements by including an FT to the wall measurement or by erroneously filling in the space between the FT and the endocardium because of inappropriate contrast and grayscale settings. Finally, it is important to conduct off-axis imaging [6,21,31,32] to verify that true septal thickness is not being altered by an adjacent FT running parallel to the IVS leading to erroneous measurements [13–15,33].

#### CLINICAL INVESTIGATION



### Left Ventricular False Tendons are Associated With Left Ventricular Dilatation and Impaired Systolic and Diastolic Function

Michael E. Hall, MD, MS, Joseph A. Halinski, BA, MS, Thomas N. Skelton, MD, William F. Campbell, MD, Michael R. McMullan, MD, Robert C. Long, MD, PharmD, Myrra N. Alexander, MD, James D. Pollard, MD, John E. Hall, PhD, Ervin R. Fox, MD, MPH, Michael D. Winniford, MD and Daisuke Kamimura, MD, PhD

#### ABSTRACT

**Background:** Left ventricular false tendons (LVFTs) are chord-like structures that traverse the LV cavity and are generally considered to be benign. However, they have been associated with arrhythmias, LV dilatation and LV dysfunction in some small studies. We hypothesized that LVFTs are associated with LV structural and functional changes assessed by echocardiography.

**Methods:** We retrospectively evaluated echocardiographic and clinical parameters of 126 patients identified as having LVFTs within the past 2 years and compared them to 85 age-matched controls without LVFTs.

**Results:** There were no significant differences in age ( $52 \pm 18$  versus  $54 \pm 18$  years,  $P = 0.37$ ), sex (55% versus 59% men,  $P = 0.49$ ), race (36% versus 23% white,  $P = 0.07$ ), systolic blood pressure ( $131 \pm 22$  versus  $132 \pm 23$  mmHg,  $P = 0.78$ ) or body mass index (BMI,  $31 \pm 8$  versus  $29 \pm 10$  kg/m<sup>2</sup>,  $P = 0.07$ ) between controls and patients with LVFTs, respectively. Patients with LVFTs had more prevalent heart failure (43% versus 21%,  $P = 0.001$ ). Patients with LVFTs had more LV dilatation, were 2.5 times more likely to have moderate-to-severe mitral regurgitation, had more severe diastolic dysfunction and reduced LV systolic function (18% lower) compared with controls (all  $P < 0.05$ ). After adjustment for covariates, basal and middle LVFT locations were associated with reduced LV systolic function ( $P < 0.01$ ), and middle LVFTs were associated with LV dilatation ( $P < 0.01$ ).




**Conclusions:** Our findings suggest that LVFTs may not be benign variants, and basal and middle LVFTs may have more deleterious effects. Further prospective studies should be performed to determine their pathophysiological significance and whether they play a causal role in LV dysfunction.

**Key Indexing Terms:** Myocardial band; Left ventricle; Cardiac dysfunction. [Am J Med Sci 2017;354(3):278–284.]



# False Tendons – Normal Variant eller Sygdom?


3 fænotyper?!








# Burmeser med Mislyd


07/06/2017 11:11:29





# False Tendons



# Differential Diagnosis



- Aortic stenosis
- Hyperthyroidism
- Hypertension
  - Chronic renal disease
- Papillary muscle malpositioned
- False tendons
- Transient Myocardial Thickening
- Myocarditis
- Myocardial fibrosis
- Dehydration
- Lymphoma
- Acromegaly
- Amyloidosis
- Intra- and inter-breed variation
- Observer variation






# Prognosis

## Population and survival characteristics of cats with hypertrophic cardiomyopathy: 260 cases (1990–1999)

John E. Rush, DVM, MS, DACVIM, DACVECC; Lisa M. Freeman, DVM, PhD, DACVN;  
Nathaniel K. Fenollosa, DVM; Donald J. Brown, DVM, PhD, DACVIM

Asymptomatic for years	• Median survival time 1129 days
Syncope	• MST 654 days
Congestive heart failure	• MST 563 days
Thromboembolism	• MST 183 days • Poor to guarded
Sudden death less than 5-10%?	• Genotype?
Genotype!?	• Future - gene therapy

Symptomatic – Median survival 194 days  
(Paine et al, 2010)



**Fig 1.** (a) Survival of 46 cats with cardiomyopathy that died before the time of publication. (b) Survival of 27 cats with cardiomyopathy that were still alive at the time of publication.

*Journal of Feline Medicine and Surgery* (2003) 5, 151–159  
doi:10.1016/S1098-612X(02)00133-X

**jfms**

### Feline idiopathic cardiomyopathy: a retrospective study of 106 cats (1994–2001)

L Ferasin<sup>\*</sup>, CP Sturgess, MJ Cannon<sup>1</sup>, SMA Caney, TJ Gruffydd-Jones, PR Wotton<sup>2</sup>


JAVMA, Vol 220, No. 2, January 15, 2002

Maiken Bach, Studieadjunkt i klinisk kardiologi og Ph.D studerende






# Ph.D. i avanceret ekkokardiografi 2025: Nye ekkokardiografiske markører for ...




Journal of Veterinary Cardiology  
Volume 41, June 2022, Pages 236-248

Non-invasive assessment of left ventricular relaxation property using color M-mode-derived intraventricular pressure gradients in cats ☆

K. Matsuura PhD<sup>a,d</sup>, M.B.T. Bach DVM<sup>b</sup>, K. Takahashi PhD<sup>c</sup>, J.L. Willesen PhD<sup>b</sup>, J. Koch PhD<sup>b,e</sup>, R. Tanaka PhD<sup>b,e</sup>




Tidlig detektion af HCM




Status: Data opmåles!

Left ventricular myocardial dyssynchrony and 2D strain in cats with hypertrophic cardiomyopathy

M.B.T. Bach, J.L. Willesen, J. Koch (et al.)




Risiko vurdering af HCM katte



Journal of Veterinary Cardiology  
Volume 36, August 2021, Pages 153-168

Detection of congestive heart failure by mitral annular displacement in cats with hypertrophic cardiomyopathy – concordance between tissue Doppler imaging–derived tissue tracking and M-mode ☆

M.B.T. Bach DVM<sup>a</sup>, J.R. Grevsen DVM, M.A.B. Kiely DVM, J.L. Willesen PhD, J. Koch PhD




Detektion af hjertesvigt





## Igangværende forskningsprojekter indenfor HCM




Der **inkluderes** NFO'er med HCM diagnosticeret før 5 års alderen!

HCM-genetik i Norsk Skovkat



Der **inkluderes** katte med HCM der skal aflives. Pjece for mere information.

Myosin funktion & Behandlingsmuligheder



I DK, fokus på familiestudier af katte med tidlig udviklet sygdomspræsentation <3år.

HCM-genetik i British shorthair

The **HALT** HCM Study  
Feline Hypertrophic Cardiomyopathy

Study **OPEN** for  
recruitment

powered by  
**TRIUM VET**

[www.hcmincats.com](http://www.hcmincats.com)



Katte med HCM  
kan registreres  
online til  
behandlingsstudie



...

07/03/2024 14:48:09  
HD



199  
1:103HR

15/08/2024 13:56:40  
HD




152  
1:146HR




# Rapamycin Inhibition of mTORC1

- Rapamycin specifically inhibits **mTORC1** by binding to an intracellular protein called **FKBP12** (FK506 binding protein 12). This complex then interacts with mTORC1, leading to its inhibition. The effects of rapamycin on mTORC1 are as follows:
- **Reduction in protein synthesis:** By inhibiting mTORC1, rapamycin reduces the synthesis of proteins involved in hypertrophy, leading to a suppression of the pathological growth of cardiomyocytes.
- **Restoration of autophagy:** Inhibition of mTORC1 allows autophagy to resume, helping cells clear out damaged proteins and organelles, improving cellular health and mitigating hypertrophic signaling.



The screenshot shows the TriviumVet website with a navigation menu (Home, Products, Clinical Trials) and a social media sidebar. The main content area features a banner for "The HALT HCM Study" (Feline Hypertrophic Cardiomyopathy) with the text "Study OPEN for recruitment" and the website "www.hcmcats.com". Below the banner is a news article titled "TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)" dated 25th June. The article text includes: "We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was officially launched at this year's American College of Veterinary Internal Medicine (ACVIM) in Minneapolis." and "The HALT Study is a pivotal, placebo-controlled trial designed to determine the effectiveness of TRIV202 in managing left ventricular hypertrophy associated with feline Hypertrophic Cardiomyopathy (HCM) over a 12-month period." and "The study is now open for recruitment, enrolling cats diagnosed with subclinical HCM offering care from a board-certified veterinary cardiologist FREE OF CHARGE."




The second screenshot shows a detailed article titled "Feline Hypertrophic Cardiomyopathy (HCM)". The text states: "TRIV202 has been researched and developed by TriviumVet and is intended to be the first treatment for subclinical hypertrophic cardiomyopathy (HCM) in cats. HCM is a serious and life-threatening condition that affects approximately 1% of cats. Prior to the onset of heart failure or other serious outcomes, HCM is currently untreatable with available therapies." and "TRIV202 is a proprietary (patent pending), delayed release, inhibitor of the mTOR pathway – a central regulator of metabolism and physiology. TriviumVet is the first company to target this pathway in cats with heart disease. We have carried out extensive formulation development to create a feline-safe, dose-appropriate product. TRIV202 is administered orally just once a week and is currently undergoing regulatory review." and "The product has been evaluated in pet cats with early (subclinical) HCM by investigators at two US cardiology centers, and results were recently published in the Journal of the American Veterinary Medical Association." A pink button labeled "Clinical Trials" is visible at the bottom.



# mTORC1 & mTORC2 Effects (Multiprotein Complexes)

- Protein synthesis and cell growth
- Lipid biosynthesis
- Inhibition of autophagy
- Metabolic regulation, including enhanced glycolysis and mitochondrial biogenesis
- Inhibition of catabolic processes
- Angiogenesis regulation
- Involvement in cellular senescence and aging
- Cardiac hypertrophy (pathological remodeling in diseases like hypertrophic cardiomyopathy)
- Modulation of inflammatory responses



The major upstream regulators of mTORC1 and mTORC2. Growth factors, amino acids like arginine and leucine, energy from glucose or other sources, cell stresses including DNA damage, and ROS stimulate mTORC1 to modulate various biological processes like mitochondrial biogenesis, nucleotide synthesis, mRNA translation (protein synthesis), lipid synthesis, and autophagy. The growth factors are the main regulators of the mTORC2 to control cell proliferation, migration, cytoskeleton remodeling, ion transport, and glucose metabolism. Created with BioRender.com



Panwar, V., Singh, A., Bhatt, M. *et al.* Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease. *Sig Transduct Target Ther* 8, 375 (2023). <https://doi.org/10.1038/s41392-023-01608-z>

# Mavacamten in HCM Treatment

- Pathophysiology: Mutations in sarcomeric proteins (e.g., myosin) lead to excessive contractility, myocardial thickening, and impaired relaxation. Overactive myosin-actin cycling increases ATP consumption and causes dysfunction


## Mechanism:

- Binds to  $\beta$ -cardiac myosin, reducing ATPase activity
- Stabilizes myosin in a "super-relaxed" state (SRX), lowering cross-bridge formation and decreasing contractile force



# Mavacamten in HCM Treatment

- Therapeutic Effects:
- Reduces hypercontractility and ATP consumption.
- Improves diastolic function, reducing symptoms like shortness of breath.
- Relieves LVOT obstruction, improving blood flow.
- May reverse myocardial hypertrophy and reduce arrhythmia risk.
- Clinical Outcomes: Improved symptoms, cardiac function, and reduced hypertrophy over time.





Difficult to continue to believe that HCM is generally a disease caused by single mutations in the sarcomere (or, in the jargon of genetics, an autosomal dominant mutation). Leading researchers today are investigating broader hypotheses about the causes of HCM (Maron et al. 2019, Harper et al. 2021, Watkins 2021).



